| pubmed-article:3372000 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3372000 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:3372000 | lifeskim:mentions | umls-concept:C0018593 | lld:lifeskim |
| pubmed-article:3372000 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3372000 | pubmed:dateCreated | 1988-7-11 | lld:pubmed |
| pubmed-article:3372000 | pubmed:abstractText | Monoclonal antibody MOv2, produced against ovarian carcinoma, was previously found to bind a carbohydrate epitope (CAMOv2) present on mucins, glycoproteins and a neutral glycolipid. In this paper, the structure of the carbohydrate epitope is determined by immunological reactivity with purified glycolipids and oligosaccharides. Using solid-phase radioimmunoassay and immunostaining of thin layer chromatograms, MOv2 binds strongly to Le(a)-active pentasaccharide ceramide. A smaller neutral glycolipid also weakly binds MOv2. Fifty percent inhibition of binding to Le(a)-active pentasaccharide ceramide is achieved with approximately 8 microM concentration of lacto-N-fucopentaose II (LNF II). Lacto-N-tetraose (LNT) also partially inhibits at about 10(3) times higher concentration suggesting that the faster migrating glycolipid antigen contains this carbohydrate sequence. Binding to Le(a)-active hapten is further confirmed by the specific inhibition of binding by authentic anti-Le(a) monoclonal antibodies but not by anti-Le(b) MOv2 antibody in a serum assay among healthy blood donors also supports these results. In conclusion, we have obtained direct evidence from several independent experiments that antibody MOv2 recognizes the Le(a)-active hapten. | lld:pubmed |
| pubmed-article:3372000 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3372000 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3372000 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3372000 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:3372000 | pubmed:issn | 0272-457X | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:CanevariSS | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:SonninoSS | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:LeoniFF | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:ColnaghiM IMI | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:MiottiSS | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:MagnaniJ LJL | lld:pubmed |
| pubmed-article:3372000 | pubmed:author | pubmed-author:PasqualeAA | lld:pubmed |
| pubmed-article:3372000 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3372000 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:3372000 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3372000 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3372000 | pubmed:pagination | 129-39 | lld:pubmed |
| pubmed-article:3372000 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:meshHeading | pubmed-meshheading:3372000-... | lld:pubmed |
| pubmed-article:3372000 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3372000 | pubmed:articleTitle | The antitumor monoclonal antibody MOv2 recognizes the Lewis A hapten. | lld:pubmed |
| pubmed-article:3372000 | pubmed:affiliation | Division of Experimental Oncology E Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy. | lld:pubmed |
| pubmed-article:3372000 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3372000 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
